Titan Biotech Limited (TITANBIO.BO) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-72.1%

₹91.19

vs ₹326.45 price

Levered DCF

₹142.66

After debt service

Piotroski score

4 / 9

Average

Altman Z-score

—

Rating

C+

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	50.64×	13.96×	14.19×	5.24×	7.99×	4.04×	3.99×	8.89×
P/B	8.34×	1.96×	2.64×	1.18×	2.01×	1.78×	0.72×	0.97×
P/S	7.34×	1.92×	2.15×	0.9×	1.4×	0.86×	0.35×	0.48×
EV / EBITDA	39.31×	10.17×	10×	4.25×	5.48×	2.84×	3.52×	5.62×
Gross margin	35.3%	53.6%	26.4%	40.5%	42.9%	47.1%	23.3%	37.8%
Operating margin	16.3%	13.6%	19.3%	36.0%	23.7%	31.2%	14.8%	11.1%
Net margin	14.5%	13.8%	15.1%	17.3%	17.6%	21.3%	8.9%	5.4%
Current ratio	3.28×	4.46×	3.69×	3.36×	3.76×	3.05×	2.16×	2.23×
Debt / equity	0.03×	0.02×	0.06×	0.08×	0.1×	0.22×	0.61×	0.74×
Interest coverage	36.85×	26.51×	27×	69.46×	33.53×	26.61×	5.03×	3.15×
Dividend yield	0.1%	0.5%	0.4%	1.0%	0.7%	0.7%	0.0%	7.9%
Payout ratio	5.5%	7.7%	6.0%	5.0%	5.7%	2.7%	0.0%	70.4%

Key metrics by fiscal year

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	16.5%	14.0%	18.6%	22.6%	25.1%	44.1%	18.0%	10.9%
Return on invested capital	12.9%	10.4%	16.6%	33.2%	22.4%	36.6%	13.0%	8.6%
Return on assets	14.0%	12.3%	15.8%	18.5%	20.1%	30.1%	9.3%	5.4%
Free cash flow yield	1.3%	3.6%	0.4%	6.5%	4.8%	11.6%	2.4%	3.3%
Earnings yield	2.0%	7.2%	7.1%	19.1%	12.5%	24.7%	25.1%	11.3%
Enterprise value	₹15.2B	₹3B	₹3.6B	₹1.3B	₹1.8B	₹1.3B	₹502.2M	₹530.1M
Net debt / EBITDA	0.1×	-0.08×	0.15×	0.12×	0.07×	0.2×	1.55×	2.31×
Cash conversion cycle (days)	170	273	172	142	206	186	207	237